S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

GRF Eagle Capital Growth Fund Inc

9.95

0.00 (0.00%)

Feb 11 2025 - Closed

Delayed by 15 minutes

Form N-PX - Annual Report of proxy voting record of management investment companies

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Eagle Capital Growth Charts.

Eagle Capital Growth Fund Inc News

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease
Tuesday 14 January 2025 (4 weeks ago) • GlobeNewswire Inc.

Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
Thursday 26 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (2 months ago) • Edgar (US Regulatory)

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus
Tuesday 19 November 2024 (3 months ago) • GlobeNewswire Inc.

Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash
Monday 18 November 2024 (3 months ago) • Business Wire

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution
Tuesday 29 October 2024 (3 months ago) • GlobeNewswire Inc.

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury
Tuesday 22 October 2024 (4 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 3 October 2024 (4 months ago) • Edgar (US Regulatory)

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat
Thursday 3 October 2024 (4 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 10 September 2024 (5 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 10 September 2024 (5 months ago) • Edgar (US Regulatory)

GigaGen Receives FDA Clearance of IND Application for Phase 1 Trial of Recombinant Polyclonal for HBV Treatment, GIGA-2339
Wednesday 31 July 2024 (6 months ago) • GlobeNewswire Inc.

More Eagle Capital Growth Fund Inc News Articles

Societe Generale Effekten

Amundi Msci Che

Intesa Sanpaolo

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions